Overview

BNHL-2015 for Children or Adolescents in China

Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with the historical study CCCG-NHL-2010.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Children's Cancer Group, China
Collaborators:
Children's Hospital Of Soochow University
Children’s Hospital of Sochow University, China
Nanjing Children's Hospital
Qilu Hospital
Qilu Hospital of Shandong University
Tianjin Medical University Cancer Institute and Hospital
Tongji Hospital
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China
West China Second University Hospital
Xiangya Hospital of Central South University
Treatments:
Cyclophosphamide
Cytarabine
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Methotrexate
Prednisone
Rituximab
Vincristine